A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.

Weijun Zhou; Angel D Oliviera; Xuhang Dai; Jeffrey S. Mugridge; Yingkai Zhang

doi:10.1021/acschembio.6c00120

May 1, 2026

A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To identify a novel covalent inhibitor fragment for the SARS-CoV-2 main protease using target-specific deep learning.
Utilized deep learning algorithms to screen for potential inhibitors of SARS-CoV-2 main protease.
Focused on optimizing inhibitor fragments for higher efficacy against the target.
Conducted evaluations of identified leads for future drug development.
Demonstrated new inhibitor leads with promising binding affinity to the SARS-CoV-2 main protease.
Highlighted successful application of deep learning for rapid drug discovery.
Indicated potential for future optimization and development of drug scaffolds.

Implication

Identifies a new covalent inhibitor fragment for SARS-CoV-2, suggesting deep learning can accelerate drug discovery.

Abstract

pockets in future optimization efforts. Together, these results demonstrate the potential for target-specific deep learning approaches to guide the rapid screening and discovery of new inhibitor leads or drug scaffolds.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69f8375e3ed186a739981831 https://doi.org/10.1021/acschembio.6c00120

View at Publisher

Ask AI

Bookmark

Share

A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.

Key Points

Implication

Abstract

Discussion

Cite This Study

A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading